ABT - Abbott Laboratories

NYSE - NYSE Delayed Price. Currency in USD
83.42
+1.37 (+1.67%)
At close: 4:01PM EDT

83.42 0.00 (0.00%)
After hours: 4:27PM EDT

Stock chart is not supported by your current browser
Previous Close 82.05
Open 82.45
Bid 83.00 x 1400
Ask 83.94 x 800
Day's Range 81.92 - 83.59
52 Week Range 60.32 - 83.59
Volume 6,093,560
Avg. Volume 5,219,615
Market Cap 147.168B
Beta (3Y Monthly) 0.85
PE Ratio (TTM) 56.59
EPS (TTM) 1.47
Earnings Date Jul 16, 2019 - Jul 22, 2019
Forward Dividend & Yield 1.28 (1.68%)
Ex-Dividend Date 2019-07-12
1y Target Est 83.06
Trade prices are not sourced from all markets
  • Abbott (ABT) Outpaces Stock Market Gains: What You Should Know
    Zacks 4 hours ago

    Abbott (ABT) Outpaces Stock Market Gains: What You Should Know

    Abbott (ABT) closed at $83.42 in the latest trading session, marking a +1.67% move from the prior day.

  • PR Newswire 2 days ago

    CARE, Abbott and the Abbott Fund Launch Partnership to Address Noncommunicable Diseases (NCDs) in Humanitarian Settings

    ATLANTA and ABBOTT PARK, Ill., June 17, 2019 /PRNewswire/ -- The global humanitarian organization CARE, the healthcare company Abbott (ABT) and its foundation the Abbott Fund today announced a three-year, $1 million program to screen, diagnose, prevent and manage noncommunicable diseases (NCDs) for people who remain displaced two years after armed conflict in Marawi City, Philippines. The partnership is among the first of its kind to address NCDs in areas affected by disasters, conflict and other humanitarian challenges.

  • PR Newswire 2 days ago

    Abbott Launches First-ever Rapid Point-of-Care HbA1c Test to Aid in the Diagnosis of Diabetes

    - Afinion™ HbA1c Dx test provides results in three minutes, enabling clinicians to develop informed, individualized care plans during patient consultation - Assay is the first and only rapid point-of-care ...

  • Abbott (ABT) Hits New 52-Week High on Solid Growth Drivers
    Zacks 2 days ago

    Abbott (ABT) Hits New 52-Week High on Solid Growth Drivers

    Abbott (ABT) gains from expansion of product portfolio and several regulatory clearances.

  • PR Newswire 5 days ago

    Abbott Declares 382ⁿᵈ Consecutive Quarterly Dividend

    ABBOTT PARK, Ill., June 14, 2019 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 32 cents per share. This marks the 382 nd consecutive quarterly ...

  • Abbott (ABT) Moves to Buy: Rationale Behind the Upgrade
    Zacks 6 days ago

    Abbott (ABT) Moves to Buy: Rationale Behind the Upgrade

    Abbott (ABT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).

  • PR Newswire 6 days ago

    New Survey Shows Millennials Can Help Avoid Blood Shortages

    ABBOTT PARK, Ill., June 13, 2019 /PRNewswire/ -- A new survey from Abbott (ABT) finds that millennials may be the key to a growing public health problem: a shortage in donated blood. Historically, 45% of blood donations in the U.S. are from people 50 and older.1 A large portion of these regular donors are baby boomers who are starting to reach an age when they develop health problems that make them ineligible to give blood. "Millennials are known for wanting to positively impact global issues, and we are hoping to see that passion applied to donating blood," said Alexander Carterson, M.D., Ph.D., global medical director, Transfusion Medicine, Abbott.

  • Traders Look to Buy Global Health Care Stocks
    Investopedia 7 days ago

    Traders Look to Buy Global Health Care Stocks

    The patterns forming on the long-term charts suggest that the global health care sector could be poised for a prolonged move higher.

  • Here’s What Hedge Funds Think About Abbott Laboratories (ABT)
    Insider Monkey 9 days ago

    Here’s What Hedge Funds Think About Abbott Laboratories (ABT)

    It seems that the masses and most of the financial media hate hedge funds and what they do, but why is this hatred of hedge funds so prominent? At the end of the day, these asset management firms do not gamble the hard-earned money of the people who are on the edge of poverty. Truth […]

  • The Zacks Analyst Blog Highlights: Mastercard, Disney, Abbott, Workday and Sun Life
    Zacks 9 days ago

    The Zacks Analyst Blog Highlights: Mastercard, Disney, Abbott, Workday and Sun Life

    The Zacks Analyst Blog Highlights: Mastercard, Disney, Abbott, Workday and Sun Life

  • Markit 9 days ago

    See what the IHS Markit Score report has to say about Abbott Laboratories.

    Abbott Laboratories NYSE:ABTView full report here! Summary * Perception of the company's creditworthiness is negative * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for ABT with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting ABT. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding ABT totaled $4.38 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swap | NegativeThe current level displays a negative indicator. ABT credit default swap spreads are at their highest levels for the past 3 years, which indicates the market's more negative perception of the company's credit worthiness.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Where Will Abbott Laboratories Be in 10 Years?
    Motley Fool 10 days ago

    Where Will Abbott Laboratories Be in 10 Years?

    Expect the healthcare giant to hew to the principles that lifted it to where it stands now.

  • Reuters 11 days ago

    CORRECTED-Abbott device helps in cutting blood sugar in type 2 diabetics - study (June 8)

    Insulin-dependent patients with type 2 diabetes saw a significant drop in their blood sugar levels after wearing Abbott Laboratories Inc's continuous glucose monitoring system for three months compared with when they were not using the device, researchers said on Saturday. The study, which was presented at the American Diabetes Association meeting in San Francisco, assessed the medical records of 363 type 2 diabetics in France, Germany and Austria between three and six months. Dr. Helene Hanaire of the University Hospital Center of Toulouse, France, one of the study authors, said having ready access to their blood glucose readings helped diabetics become more engaged with controlling their glucose levels.

  • PR Newswire 11 days ago

    New Data Show Use of Abbott's FreeStyle® Libre System Significantly Reduces HbA1c Levels in People Living with Type 2 Diabetes

    SAN FRANCISCO, June 8, 2019 /PRNewswire/ -- Today Abbott (ABT) announced new data showing use of its FreeStyle Libre system, the company's revolutionary continuous glucose monitoring (CGM) technology, significantly reduced hemoglobin A1c (HbA1c) levels for people living with Type 2 diabetes on intensive insulin therapy.2 The results were analyzed from retrospective, real-world data in three countries across Europe and presented as a late-breaker (Abstract 99-LB) at the American Diabetes Association (ADA) 79th Scientific Sessions in San Francisco. The goal of the combined analysis of three individual studies was to determine the impact of using the FreeStyle Libre system on glycemic control in people on intensive insulin therapy living with Type 2 diabetes, the most common form of diabetes where the body is unable to make enough insulin to keep blood glucose levels normal.

  • Top Research Reports for Mastercard, Disney & Abbott
    Zacks 12 days ago

    Top Research Reports for Mastercard, Disney & Abbott

    Top Research Reports for Mastercard, Disney & Abbott

  • Is Abbott Laboratories (ABT) Outperforming Other Medical Stocks This Year?
    Zacks 13 days ago

    Is Abbott Laboratories (ABT) Outperforming Other Medical Stocks This Year?

    Is (ABT) Outperforming Other Medical Stocks This Year?

  • Abbott (ABT) Gains But Lags Market: What You Should Know
    Zacks 15 days ago

    Abbott (ABT) Gains But Lags Market: What You Should Know

    Abbott (ABT) closed at $77.54 in the latest trading session, marking a +1.85% move from the prior day.

  • Abbott (ABT) Grows on EPD Amid Rhythm Management Challenges
    Zacks 15 days ago

    Abbott (ABT) Grows on EPD Amid Rhythm Management Challenges

    We are optimistic about the steady growth trend in Abbott's (ABT) EPD and Medical Devices segments on an organic basis.

  • Did Abbott Laboratories (NYSE:ABT) Use Debt To Deliver Its ROE Of 8.3%?
    Simply Wall St. 16 days ago

    Did Abbott Laboratories (NYSE:ABT) Use Debt To Deliver Its ROE Of 8.3%?

    While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...

  • Here is the 18th Most Popular Stock Among Hedge Funds
    Insider Monkey 17 days ago

    Here is the 18th Most Popular Stock Among Hedge Funds

    Many investors, including Paul Tudor Jones or Stan Druckenmiller, have been saying before the Q4 market crash that the stock market is overvalued due to a low interest rate environment that leads to companies swapping their equity for debt and focusing mostly on short-term performance such as beating the quarterly earnings estimates. In the first […]

  • Abbott (ABT) Stock Moves -0.05%: What You Should Know
    Zacks 21 days ago

    Abbott (ABT) Stock Moves -0.05%: What You Should Know

    In the latest trading session, Abbott (ABT) closed at $75.67, marking a -0.05% move from the previous day.

  • The Top Health Care Companies in the World
    Investopedia 21 days ago

    The Top Health Care Companies in the World

    An introduction to health care companies that are tops in their fields. From health care provider to pharmaceuticals, these companies have the largest global presence according to market capitalization. Learn who these health care giants are and why they may be a good investment.

  • The highest-paid CEOs by state
    Associated Press 26 days ago

    The highest-paid CEOs by state

    Here are the top paid CEOs by state for 2018, as calculated by The Associated Press and Equilar, an executive data firm. The survey considered only publicly traded companies with more than $1 billion in ...

  • CNBC 26 days ago

    One sector is making a comeback amid market volatility

    Prepare for more churn around these levels, said  Mark Tepper , president of Strategic Wealth Partners. "We're really trying to target good companies that are big players in investible themes, and health care as a sector has struggled this year but it's been resilient over the past month. As the S&P 500 has tumbled 4% this month, the XLV health care sector ETF has held slightly positive.